Related Experiment Video
Updated: Jun 27, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Adjuvant therapy for colon cancer: present and perspectives
S De Dosso1, C Sessa, P Saletti
1Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland.
Cancer Treatment Reviews
|November 18, 2008
Summary
Colon cancer is a leading cause of cancer death globally. Research is exploring prognostic factors and targeted therapies to improve adjuvant treatment for stage II colon cancer patients, refining current chemotherapy regimens.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Colon cancer ranks as the second leading cause of cancer mortality worldwide.
- Early diagnosis often reveals localized disease within the intestinal wall or regional lymph nodes.
Purpose of the Study:
- To evaluate the role of adjuvant treatment in stage II colon cancer.
- To identify prognostic factors (histopathological and molecular) for selecting patients who benefit from adjuvant therapy.
- To explore the integration of molecular targeted agents into adjuvant chemotherapy regimens.
Main Methods:
- Review of current standard adjuvant therapies for stage III colon cancer (5-fluorouracil, folinic acid, Oxaliplatin).
- Analysis of prognostic factors in stage II colon cancer.
- Investigation of novel adjuvant treatment strategies incorporating molecular targeted agents.
Main Results:
- Adjuvant therapy with 5-fluorouracil, folinic acid, and Oxaliplatin is standard for resected stage III colon cancer.
- The benefit of adjuvant treatment for stage II colon cancer remains debated.
- Molecular targeted agents are a key area of development for adjuvant therapy.
Conclusions:
- Identifying prognostic factors is crucial for tailoring adjuvant treatment in stage II colon cancer.
- Future adjuvant therapy protocols are likely to include molecular targeted agents alongside traditional chemotherapy.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...